> Contact us

Watch video

IMPLEMENTING REAL-TIME MONITORING AND MAKING IT A SUCCESS STORY

There are several success stories on how real-time monitoring has saved high value products and ensured drug availability. However, Niclas Ohlsson, CEO at TSS, believes companies need to carefully assess and plan before deciding to implement real-time monitoring in their life science supply chains.

Scroll to read on 

I

In the TSS real-time application you can follow your most valuable shipments live, all the way to the last mile. Although this type of application opens up for huge possibilities, it is important to remember that it also requires companies to think through how the organisation and its processes are affected.


This typically calls for an escalation process as well as an organization that is available 24/7, with a global operation team that can, if needed, interact and initiate corrective actions. In the complex eco system of a supply chain, that may involve different companies, experts need to be accessible and actionable.

The first impact of implementing real-time monitoring is the need for a control tower. This control tower must be able to capture all alarms, to be qualified to interpret them, and to conclude what action is suitable, and by whom

Before deciding to implement real-time monitoring, you need to ask yourself: is there a risk that we turn our organization into a reactive rather than a proactive organization? And what is the cost for that?

Niclas Ohlsson says, that, in order to assess the possible effectiveness of real-time monitoring, the supply chain’s white and dark spaces need to be identified. Depending on how your supply chain has been set up, it is important to map areas where possible actions can be taken, but also where it can not be. This information should be mapped against historical data where issues are typically initiated or escalating.


“If there is a high positive overlap, the analysis should assess the causes for the deviation. Knowing this, you need to assess how such a situation can be addressed in the field - which action is required?”


The percentage of cases that could be addressed, and the cost for these real time actions, should then be compared with a proactive action that could alternatively resolve the issue.

To make sure your real-time monitoring experience becomes a success stories, it is crucial that you know which questions to ask during the evaluation process, and what to expect from the vendor. 

> Download TSS’ buyer’s guide to real-time temperature monitoring to learn more!

Go to article: Home | Saving face: PR in pharma Go to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Hapa Company Insight Go to article: Owen MumfordGo to article: NewsGo to article: Dupont PharmaceuticalsGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: The pharma industry briefingGo to article: Scandinavian Health Ltd.Go to article: Gerteis Company InsightGo to article: GerteisGo to article: Coughs and sneezes spread diseases: charting the development of flu vaccinesGo to article: Swiss WorldCargoGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: ‘Don’t put baby in the corner’: overcoming challenges in paediatric drug developmentGo to article: Qatar AirwaysGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: Debate: should countries bring critical drug production home?Go to article: AirBridgeCargo Company InsightGo to article: AirBridgeCargoGo to article: Capsugel Company Insight Go to article: Beyond Viagra Town: profiling the Irish pharma industryGo to article: Daiichi JitsugyoGo to article: TSS Company Insight Go to article: TSSGo to article: Recurrent miscarriage: could this devastating condition have a simple cure?Go to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Public image limited: the role of PR in pharmaGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: Q&A: Gavi alliance talks immunising 300 million people Go to article: Spirax Sarco Company Insight Go to article: Spirax SarcoGo to article: Bias remorse: are cancer drug trials clear enough on outcomes?Go to article: Zenatek Go to article: B&W TekGo to article: Deals in brief powered by GlobalDataGo to article: Centaur Clinical Insight Go to article: Centaur ClinicalGo to article: The key list powered by GlobalDataGo to article: AlpexGo to article: PfanstiehlGo to article: EventsGo to article: MimotopesGo to article: NymiGo to article: Next issue